Popular COPD treatment increases risk for cardiac events, cardiac death

Sep 23, 2008

New research out of Wake Forest University School of Medicine shows that use of the most commonly prescribed once-a-day treatment for chronic obstructive pulmonary disease (COPD) for longer than one month increases the risk of cardiovascular death, heart attack or stroke by more than 50 percent.

Researchers Sonal Singh, M.D., M.P.H., and Curt Furberg, M.D., Ph.D., of Wake Forest, along with Yoon K. Loke, at the University of East Anglia, UK, conducted a meta-analysis of 17 double-blind, randomized trials involving a total of 14,783 patients with COPD. Participants received treatment with inhaled anticholinergics, another form of active therapy or a placebo inhaler.

An analysis of the data showed that use of inhaled anticholinergics for more than one month significantly increased the risk of cardiovascular death, heart attacks, or strokes in COPD patients by 58 percent.

The results appear in the Sept. 24 issue of The Journal of the American Medical Association.

Inhaled anticholinergics are a class of drugs that relax the airways and prevent them from getting narrower, making it easier to breathe. They also protect the airways from spasms that can suddenly cause the airway to become narrower (bronchospasm).

The two most commonly used inhalers from the anticholinergic class are tiotropium bromide, marketed by Pfizer as Spiriva™, and ipratropium bromide, made and marketed by Boehringer Ingelheim as Atrovent™.

"Patients with COPD who use these inhalers are at a high risk of excess serious cardiovascular events due to their use," said Singh, an assistant professor of internal medicine. "In absolute terms, if these inhalers are used for one year, nearly one in 40 patients using these inhalers may develop cardiac death related to the drug, and nearly one in 174 patients may develop a heart attack associated with these inhalers."

COPD is the fourth-leading cause of chronic morbidity and mortality in the United States, and is projected to rank fifth in 2020 in burden of disease worldwide. Cardiac death is leading cause of death among patients with COPD. Inhaled tiotropium is indicated for the long-term, once-daily maintenance treatment of symptoms associated with COPD and is the most widely used drug in COPD treatment. More than 8 million patients worldwide have used inhaled tiotropium since its approval.

The increased risk of cardiovascular events and cardiovascular death was particularly manifest in the five long-term trials (longer than 6 months) studied. In the 12 short-term trials, the direction of the drug effect was similar to that of the long-term trials.

"A regulatory reassessment of the cardiovascular safety concerns with this class of inhalers in patients with COPD is urgently needed," Singh said.

"These findings, especially the magnitude of the risk, and the consistency of the risk for heart attack, stroke and cardiac death, urge caution in the widespread use of these agents," he added. "Patients and doctors should decide whether these serious long-term cardiovascular risks outweigh their symptomatic benefits."

Source: Wake Forest University Baptist Medical Center

Explore further: Missing protein restored in patients with muscular dystrophy

add to favorites email to friend print save as pdf

Related Stories

Causes of death shifting in patients diagnosed with COPD

Jan 20, 2011

Patients suffering from chronic obstructive pulmonary disease (COPD) who are on long-term oxygen therapy (LTOT) have more to worry about than breathing difficulties. According to a new study by researchers in Sweden, COPD ...

Healthy gums may lead to healthy lungs

Jan 18, 2011

Maintaining periodontal health may contribute to a healthy respiratory system, according to research published in the Journal of Periodontology. A new study suggests that periodontal disease may increase the risk for respir ...

Recommended for you

Student seeks to improve pneumonia vaccines

16 hours ago

Almost a million Americans fall ill with pneumonia each year. Nearly half of these cases require hospitalization, and 5-7 percent are fatal. Current vaccines provide protection against some strains of the ...

Seabed solution for cold sores

18 hours ago

The blue blood of abalone, a seabed delicacy could be used to combat common cold sores and related herpes virus following breakthrough research at the University of Sydney.

Better living through mitochondrial derived vesicles

Aug 19, 2014

(Medical Xpress)—As principal transformers of bacteria, organelles, synapses, and cells, vesicles might be said to be the stuff of life. One need look no further than the rapid rise to prominence of The ...

Zebrafish help to unravel Alzheimer's disease

Aug 19, 2014

New fundamental knowledge about the regulation of stem cells in the nerve tissue of zebrafish embryos results in surprising insights into neurodegenerative disease processes in the human brain. A new study by scientists at ...

User comments : 0